Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.S. The update will likely put pressure on compounding pharmacies, which have raked in major revenues marketing knockoff versions of Novo's drug during the shortage.
The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.S. The update will likely put pressure on compounding pharmacies, which have raked in major revenues marketing knockoff versions of Novo's drug during the shortage.
